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ABSTRACT
Despite high rates of vaccination, pertussis resurgence has been reported worldwide in recent years,
including in Italy, especially in older adults.
Chronic obstructive pulmonary disease (COPD) is a respiratory disease associated with progressive
inflammation of the respiratory tract. Regional population studies have shown the prevalence of COPD
in Italy to be approximately 15% with an age-dependent increase in proportion of COPD cases.
Emerging data shows that individuals with COPD are at high risk of contracting pertussis.
Furthermore, those who develop pertussis could experience exacerbation of their pre-existent COPD
and further susceptibility to other infections.
Immunization programs in Italy currently recommend a decennial reduced-antigen-content
diphtheria-tetanus-acellular pertussis booster vaccine dose for adults. Active measures to encourage
booster vaccination, especially for high-risk adults such as those with COPD, could positively impact
pertussis morbidity and the associated healthcare burden.
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Pertussis is a highly contagious respiratory disease caused by
the bacterium Bordetella pertussis (B. pertussis) and trans-
mitted directly from the infected to the susceptible subject.1–
3 Following attachment to the cilia of the respiratory epithelial
cells, the bacterium produces toxins that have systemic effects
on immune system and locally paralyze the cilia and cause
inflammation of the respiratory tract, which subsequently
interferes with the clearing of pulmonary secretions.4 Until
recently, B. pertussis was considered to be a non-invasive
pathogen; however, recent studies have shown that the bac-
teria can enter certain cells of respiratory origin such as
alveolar macrophages5 and epithelial cells.6
Pertussis in children is characterized by an initial catarrhal
phase, presenting symptoms such as mild fever, runny nose and
cough which appear 7–10 days after infection. In typical cases,
the disease gradually progresses to the paroxysmal phase where
pertussis patients exhibit the distinct “whooping cough”. The
subsequent convalescent phase of the disease may last for several
months.2,3 In infants and children, pertussis can result in sig-
nificant pathological complications, which can be classified into
three categories: pulmonary, neurologic (acute pertussis ence-
phalopathy), and nutritional.7 Moreover, in severe cases,
extreme lymphocytosis could evoke intractable pulmonary
hypertension, respiratory failure and ultimately, death.5
In contrast, in adults, pertussis presents in an atypical
manner without the classical symptoms, rendering pertussis
diagnosis challenging, and is usually manifested as
a protracted cough and lesser severity in those who have
been previously vaccinated during childhood.8 Among ado-
lescent and adult patients, pertussis complications such as
sinusitis, otitis media, urinary incontinence, pneumonia,
weight loss, rib fracture, and fainting have been described.9
Pertussis was widespread in the pre-vaccination era, mainly
affecting children between the age of 1–9 years.10 However, the
introduction of whole-cell pertussis (wP) vaccines in the late 1940s
resulted in a substantial decline in the incidence of pertussis and its
associated mortality.3 In the 1990s, the wP vaccines were replaced
by the more defined monocomponent or multicomponent acel-
lular pertussis (aP) vaccines, with an intention to improve safety
and reduce the number of side effects.3 Neither the natural infec-
tion by B. pertussis nor vaccines against pertussis, wP or aP,
provide lifelong immunity against pertussis and healthcare autho-
rities have noticed an increase in the number of pertussis cases and
epidemic cycles worldwide in recent years.1 This strongly indicates
that despite a high level of vaccine coverage, the global threat posed
by B. pertussis infections is not adequately controlled yet. The
increasing incidence of pertussis among older children, adoles-
cents and adults, especially those who are >65 years of age or with
comorbidities and pathological conditions such as chronic
obstructive pulmonary disease (COPD) is of particular concern.
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These infected populations serve as a source of transmission to
young infants who are incompletely immunized or not immu-
nized at all and are more prone to pertussis-related complications
and even death.11,12 (Figure 1).
In order to counter this threat, certain Western countries
have implemented 10-year booster vaccine programs against
pertussis13 and health organizations such as the Center for
Disease Control and Prevention (CDC), Public Health
England, and the Global Pertussis Initiative (GPI) recommend
immunization with the reduced-antigen-content diphtheria-
tetanus-acellular pertussis (Tdap) vaccine for pregnant
women as well as others who could be in contact with new-
born children.14–16
When taking into consideration the risk of pertussis
infections in adults, especially those aged 65 years and
above, particular attention should be reserved for those
with chronic respiratory diseases. COPD is a chronic pathol-
ogy of the respiratory system, depicted by persistent and
partially reversible airflow obstruction as a result of pulmon-
ary remodeling of the bronchioles (small airway disease), the
bronchi (chronic bronchitis), and the lung parenchyma (pul-
monary emphysema).17,18 The disease presents a substantial
burden on quality-of-life (QoL) and healthcare resources
and is projected to be the third leading cause of death
worldwide by 2030.17 The prevalence of COPD in Europe
has been reported to be approximately 12% in 201019 with
a matching prevalence in Italy.20,21 Results from an
international study published in 2003 reported COPD to be
prevalent in 15% in Italian adults aged 45–97 years.20 More
recently, a multicentre study conducted across Italy showed
an age-dependent prevalence of COPD, ranging from 3.3%
in adults aged 20–44 years to 13.3% in those aged 65–84
years.21
COPD is often a result of long-term external damages to
the respiratory system, either through involuntary exposure to
environmental pollutants or voluntary lifestyle practices such
as smoking. The sustained inflammation of airways leads to
the destruction or loss of lung tissue (emphysema) and scar-
ring (remodeling and fibrosis).22 The inflammatory response
in COPD is modulated by the immune system (migration of
T and B cells, neutrophils, and macrophages to the lung) and
pro-inflammatory cytokines (tumor necrosis factor-alpha,
interferon-gamma, interleukin [IL]-1, IL-6, IL-8, IL-17, IL-
18, and IL-32).23 In addition to a weakened immune system,
as a result of receiving immunosuppressive therapies (corti-
costeroids) in the long term, COPD patients also have struc-
tural modifications of the respiratory tract with inflammation
and hyper-production of mucus, defects in the load of the
ciliated epithelium, and a deficiency in innate and acquired
immunity.24
This review aims to inform healthcare professionals,
patients and the general population on the possibility of
COPD being a risk factor for pertussis and on the value of
the Tdap booster vaccination in adults and older adults with
Figure 1. The pertussis cycle. B. pertussis, Bordetella pertussis The reduction of natural immunity in adulthood not only renders people susceptible to pertussis
infections but also makes them reservoirs of Bordetella pertussis which can transmit the infection to the unvaccinated population.12
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COPD. To prepare this manuscript, a non-systematic, narra-
tive literature review was carried out. References were mainly
retrieved from PubMed and Embase up to February 2019 by
combining the following keywords: pertussis, whooping
cough, COPD, adults, vaccination, Tdap vaccines, Italy,
diphtheria, tetanus. Other technical or scientific documents
were retrieved from Google searches.
Potential relationship between COPD and host
immunity
Besides its impact on QoL, productivity, and healthcare costs,
COPD is associated with various comorbidities – lung cancer,
cardiovascular disease, hypertension, and diabetes.25 However,
the most significant issue in patients with COPD is their suscept-
ibility to bacterial and viral infections.24 Under normal circum-
stances, the epithelial lining of the respiratory tract is an efficient
barrier against infectious agents despite persistent exposure.
However, various molecular and cellular processes of COPD lead
to pathologic changes, especially in the mucociliary function,
which results in the disruption of this innate defensemechanism.24
One of the main causative factors of COPD is long-term
cigaret smoking.26 The effect of smoking on the elevated
susceptibility of smokers to respiratory tract infections of
bacterial and/or viral etiology is well documented. Various
reports since the population-based Tecumseh study published
in 197527 have demonstrated a higher risk of developing acute
respiratory infections in patients with COPD who were also
smokers;28 cigaret smoking has also been implicated in patho-
gen-induced exacerbation of COPD.29 Cigaret smoke has been
postulated to exert its immunosuppressive effects via altered
mucociliary function and gap junctions of epithelial cells;
impaired functionality of alveolar macrophages, dendritic
cells, and natural killer cells; neutrophil-mediated epithelial
cell damage; and lowered humoral and cell-mediated
immunity.30 In addition, it is also proposed that cigaret
smoke increases pathogenic virulence and antibiotic
resistance.30 Hence, smoking constitutes a significant risk
factor for infections in COPD patients.31
Episodes of exacerbations in COPD lay a huge burden, not
only on morbidity and mortality of the disease, but also on
healthcare resources, and are mainly a result of microbial
infections.24,31 Moreover, microbial colonization of the pul-
monary tissue further increases the inflammatory burden and
accelerates disease progression in COPD.24
Clinical evidence on the association of COPD and
pertussis
While the association between COPD and pertussis in clinical
settings has not been investigated extensively, some prelimin-
ary studies have shown, albeit in a non-definitive manner, an
increase in the risk of pertussis in patients with COPD as
compared to non-COPD patients.32,33
In their pilot study, Bonhoeffer et al.32 assessed patients with
acute exacerbations of chronic bronchitis (AECB) (N = 26) for
a concomitant presence of Bordetella infection using nasophar-
yngeal swabs for culture, polymerase chain reaction, and blood
samples for serology. The investigators discovered that eight of
the patients (31%) were seropositive for Bordetella infections,
five of them (19%) being confirmed by ELISA technique to be
due to B. pertussis.32
Following a case–control study comparing the seropreva-
lence of B. pertussis in 90 patients with COPD with an equal
number of control patients without COPD, Hashemi et al.33
reported no significant association between COPD and anti-
pertussis toxin (PT) IgA seropositivity (p = 0.448), indicative
of recent infection. In contrast, they observed a statistically
significant association between COPD and anti-PT IgG ser-
opositivity (p < 0.001), implying a history of infection and
which could be indicative of persistent subclinical infections.
While the investigators could not discern any association
between B. pertussis seroprevalence and severity of COPD,
the colonization by B. pertussis could serve as a potential
risk factor for the development of COPD.33
These preliminary findings which hint at an association
between B. pertussis and COPD were also confirmed in
a retrospective cohort study conducted in the United States
(US) which aimed at ascertaining the incidence and economic
burden of diagnosed pertussis in individuals ≥11 years with
COPD or asthma. The study analyzed records from a large
group of eligible patients who had been diagnosed with per-
tussis and had pre-existing asthma or COPD and compared
these to records from individuals diagnosed with pertussis but
without asthma or COPD.34
The salient findings of this study34 on the number of
diagnosed pertussis among adolescents and adults with pre-
existing COPD or asthma are summarized in Table 1.
The difference in the likelihood of hospitalization after
pertussis diagnosis is depicted here as follows:
● The likelihood of being hospitalized, irrespective of the
duration of the observation period, was higher in
patients with COPD than in controls.
● Patients with diagnosed pertussis and pre-existing COPD
accrued significantly (p < 0.0001) more healthcare costs
than controls (patient without a diagnosis of COPD).
In a study conducted among 464 hospitalized pertussis case-
patients in seven US states in 2010–2014, 165 reported at least
one underlying condition on past medical history, 89.2% of
them being ≥21 years old and 31.4% with a history of asthma
and/or COPD.35
Lastly, the findings from a recent study led by authors from
CDC, which evaluated severe pertussis infections across var-
ious states in the US during the period 2011–2015, showed
that 14.5% of patients aged 21–64 years and 26.8% of those
≥65 years who were hospitalized for pertussis also presented
with COPD indicating that underlying COPD may contribute
to the clinical severity of pertussis infections.36
Age-related changes in adaptive and humoral immunity in
adults result in immunosenescence, i.e., a diminished immune
response against certain diseases.37 These changes can not
only result in infections in such susceptible adults but also
result in them becoming reservoirs of the causative agents,
infecting those who cannot be vaccinated. Pertussis is still
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endemic and outbreaks have been reported.38 Morbidities
such as COPD are known to result in susceptibility to infec-
tious agents which in turn can lead to episodes of exacerba-
tions of COPD in these patients. Moreover, since it has been
reported that pertussis protection is not lifelong unless
a vaccine booster is given,39 it could be postulated that specific
disease-susceptible populations such as those presenting with
COPD, could be especially prone to pertussis infections.
In other words, one can hypothesize a type of vicious cycle,
where the chronic disease promotes the onset of the infection,
in this case by B. pertussis, and where the infection itself
promotes the progression of the chronic disease40 (Figure 2).
Existing international recommendation on Tdap
booster in COPD patients
On the basis of the COPD patient’s susceptibility to infections and
the continually evolving clinical evidence, the Global Initiative for
Chronic Obstructive Lung Disease (GOLD)41 and the CDC have
recommended vaccination schedules in patients with chronic
respiratory disease.40 Thereby, seasonal influenza and pneumo-
coccal vaccination are already recommended for COPD
patients.40,41 Findings from population-based studies suggested
that COPD patients, particularly the older adults, had decreased
risk of cardiac comorbidities when they were vaccinated by these
vaccines.42,43 Moreover, an analysis of the effectiveness of influ-
enza and pneumococcal vaccination in COPD patients in redu-
cing the incidence of influenza-related illness and pneumococcal
pneumonia showed that the incidence of adverse events was
comparable between the vaccinated and control groups, thereby
establishing an acceptable safety profile for both vaccines.44
For pertussis prevention, the CDC recommends a single
dose of Tdap for adults aged 19 years or older who have not
received a previous Tdap vaccine, and this also applies to
patients with chronic respiratory disease.40,45 In Europe, the
European Center for Disease Prevention and Control (ECDC)
has made adult vaccination recommendations.46 GOLD
guidelines have not yet incorporated a specific recommenda-
tion of Tdap booster in COPD patients.41
Pertussis, diphtheria, and tetanus in italy
As the decennial Tdap dose allows for simultaneous booster-
ing of the immunity against pertussis, diphtheria, and tetanus,
the Italian epidemiology of the three diseases is briefly
reviewed in this section.
Recent data published by the Istituto Superiore di Sanità
(National Institute of Health), technical body of the Italian
Ministry of Health, shows a resurgence of B. pertussis with an
increased incidence not only in infants and children47 but also
in adults and older adults in Italy.48 Comparison of seropre-
valence data from two collection periods – 1996–1997 and
2012–2013 – shows a substantial increase in the proportion of
seropositive people, especially in those >60 years of age
(38.8% vs. 18.6%; p < 0.0001).48
Disease under-recognition and under-notification is a major
hindrance to the awareness of the real burden of pertussis.47
Pertussis has been identified by the Istituto Superiore di Sanità
(National Institute of Health) as an emerging problem in Italy.
Hence, the 2017–2019 Italian National Immunization Prevention
Plan (PianoNazionale di PrevenzioneVaccinale, PNPV)hasmade
provision for pertussis boosters for adolescents as well as for adults
and older adults every 10 years.49 This measure aims to achieve
individual protection as well as to reduce B. pertussis circulation
and transmission to unvaccinated population such as infants.48
The causative agents behind diphtheria and tetanus are the
bacteria Corynebacterium diphtheriae and Clostridium tetani,
respectively.50,51 Whereas Corynebacterium diphtheriae is
transmitted from person to person or via cutaneous
diphtheria lesions,50 Clostridium tetani enters the human
body through open wounds or tissue injuries that come in
contact with materials infected with Clostridium spores.51
Table 1. Summary of the findings from a United States retrospective cohort study evaluating the incidence and economic burden of diagnosed pertussis in
individuals with COPD or asthma.34
a) Incidence of diagnosed pertussis among adolescents and adults with pre-existing COPD or asthma




Relative risk vs. patients with no
pre-existing COPD (95% CI)
Patients with pre-existing COPD and
pertussis
1,313 1,940 0.176 (0.166–0.185) 2.533 (2.396-2.678)
Patients with pre-existing COPD and
no pertussis
2,681,930 7,476,119
Patients with no pre-existing COPD or
asthma and pertussis
20,672 48,521 0.069 (0.068–0.070) −
Patients with no pre-existing COPD or
asthma and no pertussis
124,228,622 298,178,050
b) Difference in likelihood of hospitalizations after pertussis diagnosis





All cause ≥1 hospital admission (%)a 12.24 6.41 5.83
Pertussis-related ≥1 hospital admission (%)b 4.08 2.33 1.75
CI, confidence interval; COPD, chronic obstructive pulmonary disease; N, number.
COPD, chronic obstructive pulmonary disease; N, number.
aAll-cause hospitalizations reflect the difference in the percentage of patients with hospitalization during the 45-day period post-pertussis index date (date of the first
observed pertussis diagnosis minus 15 days) relative to the 45-day period pre-pertussis index date.
bPertussis-related hospitalizations reflect the percentage of patients with hospitalization related to pertussis in the 45 days post-pertussis index date (date of the first
observed pertussis diagnosis minus 15 days)
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Diphtheria and tetanus pathologies are mediated by their
respective bacterial toxins. Since tetanus is directly acquired
from the environment, herd immunity is not possible
although in some countries, maternal immunization protect-
ing infants during the neonatal period is recommended.51,52
Serologic protection decreases with increasing age. In
a seroprevalence study describing tetanus epidemiology in
Italy from 2001 to 2010, it has been reported that less than
30% of subjects aged ≥65 years had protective tetanus anti-
body levels.53 Approximately 50 cases of tetanus are notified
in Italy every year, of which approximately 80% are in the
subjects aged ≥64 years, mostly women, and with an average
number of 21 deaths per year.53
For diphtheria, immunity depends on presence of antibodies
to the diphtheria toxin at the time of infection and cell-
mediated immunity may also contribute. For neonates, mater-
nal antibodies delivered through the placenta could provide
passive immunity for the first few months.50 Diphtheria sero-
prevalence data collected from eight Italian cities in the mid-
90s has revealed a progressive reduction in the proportion of
subjects with protective anti-diphtheria antibody titers with
increasing age and approximately one-third (33.4%) of subjects
>60 years of age had antitoxin levels below protective
concentrations.54 A more recent study conducted in Austria
discovered that 65% of subjects >60 years of age did not have
protective diphtheria antibody titers at the time of receiving
a booster vaccine. Five years after booster vaccination, this
percentage further declined to 45%.55
Tdap booster recommendations in italy
PNPV 2017–2019 is a guidance document which aims at har-
monizing immunization policies across Italy. Italian health
authorities have addressed the call for action by the WHO,
the Council of European Union (EU), and ECDC to promote
and support vaccination policies to overcome the growing
“vaccine hesitancy”.56 As one of the strategies to achieve this,
PNPV allows for vaccines to be actively offered free-of-charge
to target populations.57
One of the novel policies adopted by PNPV is the recom-
mendation of the Tdap vaccine for adults and older adults,
Figure 2. Correlation between respiratory infectious episodes and COPD. COPD, chronic obstructive pulmonary disease. Depicted is a cyclic relationship between
COPD and respiratory infections such as pertussis. The presence of COPD renders the patient susceptible to infection by Bordetella pertussis which in turn can
contribute to the exacerbation of COPD.
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every 10 years.49 More precisely, the novelty lies in the addi-
tion of the pertussis component to the diphtheria-tetanus
vaccine (Td) previously recommended.
The Italian Ministry of Health has recently reiterated that
all the vaccinations included in the national schedule were to
be included in the new Essential Levels of Assistance (LEA in
Italian), i.e., healthcare assistance which is guaranteed to every
Italian citizen. This mandate further states the obligation of
the Regions to offer for free vaccinations, which, although not
mandatory, are provided for in the PNPV.58
Tdap vaccines are available, recommended, help to pro-
tect against three diseases simultaneously, and are generally
well tolerated.59 As a support for healthcare providers, the
Guide of Contraindications to Vaccination,60 produced by
eminent experts in vaccinology, in collaboration with
national institutions in Italy (Ministry of Health, Italian
Institute of Health, National Drug Agency, etc.), highlights
that the contraindications to Tdap vaccination in adult and
older adults are only confined to a few conditions (Table
2),60 thereby making a strong case for vaccinating COPD
patients against pertussis.
The unmet need for Tdap booster vaccination in
COPD patients in the italian context
In Italy, vaccination coverage figures are collected by the
Ministry of Health for individuals aged ≤18 years.61 For
those aged >18 years, the vaccination coverage is moni-
tored for influenza only. In 2018, this coverage was of
52.7% for Italians ≥65 years old.62 In an Italian
Respiratory Society web-based survey conducted among
Italian pneumologists, 81% of the participants declared
that they recommend influenza vaccination to their
patients.63 However, a mean annual influenza vaccine
coverage of only 20.2% (95% CI 18.4–22.1%) has been
reported among Italian patients aged 18–64 years with
chronic respiratory diseases in 2015–2018.64
Vaccination coverage for the other recommended pneu-
mococcal and zoster vaccines among Italian ≥65 years of age
were estimated to be around 30% and 14%, respectively.65
These low-reported coverages of recommended vaccines
among older Italian adults, especially those with chronic
respiratory diseases, and the lack of national pertussis
vaccination coverage monitoring programs among this popu-
lation suggest an unmet need of pertussis prevention among
COPD patients in the Italian context.
The primary goal of promoting the decennial Tdap booster
vaccination in adults and older adult patients with COPD is to
protect this susceptible group from developing pertussis and
thus to reduce disease transmission (Table 3).
This is particularly worth in countries like Italy where
a resurgence of the circulation of B. pertussis among adults
has been reported and where Tdap decennial vaccination
promotion and coverage appears to be suboptimal.
On this basis, as summarized in Figure 3, the healthcare
providers engaged in vaccination programs or taking care of
COPD patients are encouraged to promote the value of Tdap
decennial booster to achieve public health objectives stated by
the PNPV and to protect COPD patients from pertussis and
potential subsequent negative clinical worsening of their
chronic disease.
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Table 2. General or transient contraindications to Tdap booster.60
Diphtheria (Pediatric and Adult) Tetanus Pertussis (Adult)






attributable to another cause










Encephalopathy within seven days of
administration of previous doses of aP (pediatric
dosage) vaccine or ap (adult dosage) vaccine not
attributable to other causes.
Severe allergic reaction
(anaphylaxis) to









a component of the
vaccine.
Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine; aP, acellular pertussis (pediatric dosage); ap, acellular pertussis (adult dosage)
Table 3. Objectives of decennial Tdap booster in patients with COPD.
Vaccinate the patient with COPD every ten years with Tdap to:
Help protect the patient from acute infectious episodes of pertussis
Help reduce the risk of hospitalization
Help reduce respiratory symptoms due to pertussis infection
Boosting immune response against tetanus and diphtheria
Potentially counter the spread of pertussis in the community (reducing the
risk of pertussis in infants and family members)
COPD, chronic obstructive pulmonary disease; Tdap, reduced-antigen-content
diphtheria-tetanus-acellular pertussis vaccine
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